[Form 4] MiNK Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MiNK Therapeutics director Peter Behner was granted a stock option on 09/09/2025 to buy 3,225 shares of common stock at an exercise price of $15.36 per share. The option was reported on Form 4 filed 09/11/2025 and is exercisable through 09/09/2035. The option vests in full on the one-year anniversary of the grant date provided Mr. Behner continues to serve on the company's board through that date. Following the grant, Mr. Behner beneficially owns 3,225 shares via this option, held directly.

Positive

• Equity alignment: Director received an option grant that aligns interests with shareholders through equity ownership
• Clear vesting: Option vests in full after one year, providing transparent retention incentives

Negative

• Potential dilution: Grant represents additional outstanding option shares (3,225) which could dilute shareholders when exercised

Insights

Securities Analyst

TL;DR: A routine director option grant of 3,225 shares at $15.36 with a ten-year term and one-year cliff vesting; modest in size.

This Form 4 discloses a typical equity compensation event for a non-employee director. The grant size (3,225 options) and a ten-year expiration are consistent with long-term alignment practices. The one-year full-vesting condition ties retention to continued board service. There is no indication of accelerated vesting, cashless exercise, or other atypical terms disclosed here.

Corporate Governance Expert

TL;DR: Governance signal: standard director equity award that aligns incentives but contains no extraordinary governance provisions.

The filing shows a straightforward stock option award reported under Section 16. The disclosure includes exercise price, grant date, expiration, vesting condition, and direct ownership post-grant. From a governance perspective, the one-year cliff is a common retention mechanism; the record does not show related-party complexities or changes in control provisions in this disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behner Peter

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.36	09/09/2025		A		3,225		(1)	09/09/2035	Common Stock	3,225	$0	3,225	D

Explanation of Responses:

1. The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

	By: /s/ Christine Klaskin, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Peter Behner report on Form 4 for MiNK Therapeutics (INKT)?

He reported a stock option grant dated 09/09/2025 to purchase 3,225 shares at an exercise price of $15.36 per share.

When does the option awarded to Peter Behner vest and expire?

The option vests in full on the one-year anniversary of the grant date (subject to continued board service) and expires on 09/09/2035.

How many shares does Peter Behner beneficially own following the reported transaction?

Following the reported transaction, he beneficially owns 3,225 shares represented by the option, held directly.

What is the exercise price of the option reported on Form 4?

The exercise (conversion) price is $15.36 per share.

Who signed the Form 4 filing for the reporting person?

The Form 4 was signed by Christine Klaskin, Attorney-in-Fact, on behalf of the reporting person on 09/11/2025.